Status epilepticus--what does it mean?
Anaphylm sublingual film demonstrates positive results in pediatric patients with severe allergic reactions
Aquestive Therapeutics reports positive pediatric study results for Anaphylm, supporting its FDA submission for treating severe allergic reactions.
Food Insecurity and the Dangers of Infant Formula Dilution
Navepegritide NDA submitted to treat children with achondroplasia
Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.
Demystifying Infant Formula
Weekly review: Multiple FDA approvals, expert discussions and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
FDA approves fitusiran for hemophilia A, B patients aged 12 years and up
Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.
